{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-remote-central-sdv-for-decentralized-trials”
},
“headline”: “SOP for Remote/Central SDV for Decentralized Trials”,
“description”: “This SOP defines standardized procedures for remote and central source data verification (SDV) in decentralized clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP, covering secure data access, monitoring, audit trails, privacy, and inspection readiness.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Remote/Central SDV for Decentralized Trials

Purpose

The purpose of this SOP is to establish standardized procedures for remote and central source data verification (SDV) in decentralized clinical trials. Remote/central SDV ensures data quality, regulatory compliance, and subject safety while reducing the need for onsite monitoring.

Scope

This SOP applies to sponsors, CROs, investigators, monitors, data managers, and QA staff involved in decentralized clinical trials. It covers processes for remote access to source data, central monitoring workflows, data verification, audit trails, and regulatory inspection readiness.

Responsibilities

• Sponsor: Provides oversight, ensures technology compliance, and approves monitoring plans.
• Investigator: Grants secure access to source data and ensures subject confidentiality.
• Monitor: Conducts remote SDV and documents findings in monitoring reports.
• CRO: Manages monitoring platforms and coordinates with sites.
• QA: Audits remote SDV processes and ensures compliance with regulations.

Accountability

The Sponsor’s Clinical Data Management Head is accountable for remote and central SDV oversight. Investigators are accountable for ensuring data accuracy and access compliance at site level.

Procedure

1. Planning and Preparation
1.1 Develop a monitoring plan specifying remote and central SDV procedures.
1.2 Document in Remote Monitoring Plan Log (Annexure-1).

2. Secure Data Access
2.1 Provide authorized monitors with role-based secure access to EHRs and eSource systems.
2.2 Maintain access details in Secure Access Log (Annexure-2).

3. Source Data Verification (SDV)
3.1 Verify subject-level data (e.g., demographics, visit dates, lab results) remotely.
3.2 Document findings in Remote SDV Log (Annexure-3).

4. Central Monitoring
4.1 Conduct data trend analysis across multiple sites.
4.2 Identify outliers or protocol deviations.
4.3 Document in Central Monitoring Log (Annexure-4).

5. Data Privacy and Confidentiality
5.1 Comply with GDPR, HIPAA, and local data protection rules.
5.2 Mask identifiers where possible.
5.3 Maintain entries in Data Privacy Compliance Log (Annexure-5).

6. Audit Trail and Documentation
6.1 Maintain audit trails of all remote access and SDV activities.
6.2 Record in Audit Trail Log (Annexure-6).

7. Reporting
7.1 Generate remote monitoring reports within 10 working days of activity.
7.2 File in TMF and ISF.

8. Inspection Readiness
8.1 Ensure all SDV records are inspection-ready.
8.2 Document inspection simulations in Inspection Readiness Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• SDV: Source Data Verification
• CRO: Contract Research Organization
• QA: Quality Assurance
• EHR: Electronic Health Record
• TMF: Trial Master File
• ISF: Investigator Site File
• GCP: Good Clinical Practice
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization

Documents

1. Remote Monitoring Plan Log (Annexure-1)
2. Secure Access Log (Annexure-2)
3. Remote SDV Log (Annexure-3)
4. Central Monitoring Log (Annexure-4)
5. Data Privacy Compliance Log (Annexure-5)
6. Audit Trail Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)

References

• FDA – Guidance on Remote Monitoring
• EMA – Remote Monitoring Guidance
• CDSCO – Remote SDV in Decentralized Trials
• ICH GCP – Data Monitoring and Verification
• WHO – Decentralized Trials Monitoring

Version: 1.0

Approval Section

Annexures

Annexure-1: Remote Monitoring Plan Log

Annexure-2: Secure Access Log

Annexure-3: Remote SDV Log

Annexure-4: Central Monitoring Log

Annexure-5: Data Privacy Compliance Log

Annexure-6: Audit Trail Log

Annexure-7: Inspection Readiness Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Remote-Central-Monitoring-Procedures”
},
“headline”: “SOP for Remote and Central Monitoring Procedures in Clinical Trials”,
“description”: “This SOP outlines standardized processes for conducting remote and central monitoring in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP guidance while supporting risk-based monitoring models.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Remote/Central Monitoring Procedures

Purpose

The purpose of this SOP is to establish standardized procedures for conducting remote and central monitoring of clinical trials. These approaches complement or replace traditional onsite monitoring in specific scenarios, allowing continuous oversight of trial conduct, subject safety, and data integrity while supporting risk-based monitoring (RBM) frameworks.

Scope

This SOP applies to sponsors, CROs, CRAs, data managers, and QA officers engaged in clinical trial oversight. It covers remote monitoring (site-level review conducted offsite) and central monitoring (system-level oversight using aggregated data). It applies to EDC, CDMS, eTMF, safety databases, and laboratory systems used for clinical data management.

Responsibilities

• Sponsor: Approves remote/central monitoring strategies and ensures compliance with ICH GCP.
• Clinical Operations Manager: Defines monitoring methods, visit schedules, and escalation triggers.
• CRA/Monitor: Conducts remote monitoring visits, documents findings, and communicates with sites.
• Central Monitoring Team: Performs centralized data review, trend analysis, and signal detection.
• PI: Provides secure remote access to subject records and responds to monitoring queries.
• QA Officer: Verifies monitoring documentation and inspects RBM implementation.

Accountability

The sponsor is accountable for ensuring remote and central monitoring activities are conducted per protocol, GCP, and regulatory requirements. Clinical Operations is accountable for execution, while QA ensures oversight and compliance.

Procedure

1. Planning Remote/Central Monitoring
Conduct risk assessment to determine feasibility of remote or central monitoring.
Define critical data elements and processes requiring remote oversight.
Document monitoring strategy in Monitoring Plan (Annexure-1).

2. Remote Monitoring Preparation
Notify site at least 2 weeks prior to scheduled remote monitoring session.
Ensure secure remote access is granted through validated portals.
Prepare Remote Monitoring Checklist (Annexure-2).

3. Conduct of Remote Monitoring
CRA reviews eCRFs, informed consent scans, drug accountability records, and training logs remotely.
Conduct video/teleconferences with PI and staff to address open queries.
Document discrepancies in Remote Monitoring Report (Annexure-3).

4. Central Monitoring Activities
Aggregate site data into centralized dashboards.
Analyze KRIs (e.g., SAE reporting delays, outlier data trends, high protocol deviations).
Generate Central Monitoring Review Report (Annexure-4).

5. Documentation and Reporting
File remote and central monitoring reports in TMF.
Communicate findings to site and sponsor within 7 working days.
Initiate CAPA for significant findings (Annexure-5).

6. Frequency
Remote monitoring conducted every 4–6 weeks or as per risk profile.
Central monitoring performed continuously or monthly depending on trial design.

7. Escalation
Critical findings such as fraudulent data, subject safety concerns, or repeated non-compliance must be escalated within 24 hours.
Record in Escalation Log (Annexure-6).

8. Archiving
Archive monitoring reports, dashboards, checklists, and CAPA documentation in TMF/ISF.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• RBM: Risk-Based Monitoring
• KRI: Key Risk Indicator
• SDV: Source Data Verification

Documents

1. Monitoring Plan (Annexure-1)
2. Remote Monitoring Checklist (Annexure-2)
3. Remote Monitoring Report (Annexure-3)
4. Central Monitoring Review Report (Annexure-4)
5. CAPA Log (Annexure-5)
6. Escalation Log (Annexure-6)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Reflection Paper on RBM
• CDSCO – Clinical Monitoring Guidelines
• WHO – Remote Monitoring Practices

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Plan

Annexure-2: Remote Monitoring Checklist

Annexure-3: Remote Monitoring Report

Annexure-4: Central Monitoring Review Report

Annexure-5: CAPA Log

Annexure-6: Escalation Log

Revision History

For more SOPs visit: Pharma SOP